Compare GSK plc (GSK) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? GSK plc trades at $52.68 (market cap $101.34B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.64. The key difference: GSK plc pays a 3.49% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and GSK plc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| GSK | VNQI | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | — |
52-Week High | $61.18 | $50.76 |
52-Week Low | $36.20 | $43.26 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.56, up 0.49% today, with neutral technical signals from both moving averages and oscillators. The ETF provides international real estate diversification with 682 holdings across 30+ countries, featuring a 0.12% expense ratio and 4.6% dividend yield. Recent analysis highlights its cost advantage over competitors and recovery potential as global real estate transactions are expected to grow over 10% in 2026.
The ETF offers attractive diversification benefits for U.S. investors seeking international real estate exposure at low cost, though it has underperformed domestic counterparts in total returns. Key risks include currency fluctuations, international market volatility, and interest rate sensitivity. Current valuation metrics show P/B of 0.9x and P/E of 11.9x, suggesting reasonable pricing for global real estate assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
